Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH) was written by Jimenez, Cesar;Ventura-Cots, Meritxell;Sala, Margarita;Calafat, Margalida;Garcia-Retortillo, Montserrat;Cirera, Isabel;Canete, Nuria;Soriano, German;Poca, Maria;Simon-Talero, Macarena;Altamirano, Jose;Lucey, Michael;Garcia-Tsao, Guadalupe;Brown, Robert S. Jr;Schwabe, Robert F.;Verna, Elizabeth C.;Schnabl, Bernd;Bosques-Padilla, Francisco;Mathurin, Philippe;Caballeria, Juan;Louvet, Alexandre;Shawcross, Debbie L.;Abraldes, Juan G.;Genesca, Joan;Bataller, Ramon;Vargas, Victor. And the article was included in Liver International in 2022.Product Details of 80621-81-4 This article mentions the following:
Alc. hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort. This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end-stage liver disease (MELD). We evaluated bacterial infections, liver-related complications, mortality and liver function tests after 90 days. Twenty-one and 42 patients were included in the rifaximin and control groups respectivley. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, resp. (p = .049), with a lower incidence of acute-on-chronic liver failure (ACLF) linked to infections within the treatment group. Liver-related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient resp.) (p = .01). Mortality was lower in the treated vs. the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment. Rifaximin is safe in severe AH with a significant redection in clin. complications. A lower number of infections and a trend towards a lower ACLF and mortality favors its use in these patients. In the experiment, the researchers used many compounds, for example, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4Product Details of 80621-81-4).
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4) belongs to benzofurans derivatives. Benzofuran is a core structural unit found in many naturally occurring compounds with multidirectional biological activities. They are also prone to polymerisation in the presence of concentrated mineral acids and Lewis acids.Product Details of 80621-81-4
Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem